173 related articles for article (PubMed ID: 37741761)
1. Effectiveness of various COVID-19 vaccine regimens among 10.4 million patients from the National COVID Cohort Collaborative during Pre-Delta to Omicron periods - United States, 11 December 2020 to 30 June 2022.
Fu Y; Wu K; Wang Z; Yang H; Chen Y; Wu L; Yanagihara R; Hedges JR; Wang H; Deng Y;
Vaccine; 2023 Oct; 41(42):6339-6349. PubMed ID: 37741761
[TBL] [Abstract][Full Text] [Related]
2. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant.
Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L
Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006
[TBL] [Abstract][Full Text] [Related]
4. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
Abu-Raddad LJ; Chemaitelly H; Ayoub HH; AlMukdad S; Yassine HM; Al-Khatib HA; Smatti MK; Tang P; Hasan MR; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R
N Engl J Med; 2022 May; 386(19):1804-1816. PubMed ID: 35263534
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era.
Ioannou GN; Bohnert ASB; O'Hare AM; Boyko EJ; Maciejewski ML; Smith VA; Bowling CB; Viglianti E; Iwashyna TJ; Hynes DM; Berry K;
Ann Intern Med; 2022 Dec; 175(12):1693-1706. PubMed ID: 36215715
[TBL] [Abstract][Full Text] [Related]
6. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
[TBL] [Abstract][Full Text] [Related]
7. Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines.
Kelly JD; Leonard S; Hoggatt KJ; Boscardin WJ; Lum EN; Moss-Vazquez TA; Andino R; Wong JK; Byers A; Bravata DM; Tien PC; Keyhani S
JAMA; 2022 Oct; 328(14):1427-1437. PubMed ID: 36156706
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant.
Eick-Cost AA; Ying S; Wells N
JAMA Netw Open; 2022 Apr; 5(4):e228071. PubMed ID: 35442453
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness and duration of protection of ChAdOx1, CoronaVac, BNT162b2, mRNA-1273, and Ad26.COV2.S COVID-19 vaccines for symptomatic and hospitalized Mu, Delta, and Omicron: A test-negative case-control study.
Paternina-Caicedo A; Quevedo DS; Ríos DS; Moyano D; Alvis-Guzmán N; Alviz-Zakzuk NR; Salcedo F; Moyano L; Ramírez-Suarez J; Smith AD; De la Hoz-Restrepo F
Vaccine; 2023 Oct; 41(42):6291-6299. PubMed ID: 37679278
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study.
Monge S; Rojas-Benedicto A; Olmedo C; Mazagatos C; José Sierra M; Limia A; Martín-Merino E; Larrauri A; Hernán MA;
Lancet Infect Dis; 2022 Sep; 22(9):1313-1320. PubMed ID: 35658998
[TBL] [Abstract][Full Text] [Related]
11. Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes.
Lin DY; Gu Y; Xu Y; Wheeler B; Young H; Sunny SK; Moore Z; Zeng D
JAMA; 2022 Oct; 328(14):1415-1426. PubMed ID: 36155617
[TBL] [Abstract][Full Text] [Related]
12. Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study.
Bohnert AS; Kumbier K; Rowneki M; Gupta A; Bajema K; Hynes DM; Viglianti E; O'Hare AM; Osborne T; Boyko EJ; Young-Xu Y; Iwashyna TJ; Maciejewski M; Schildhouse R; Dimcheff D; Ioannou GN
BMJ; 2023 May; 381():e074521. PubMed ID: 37220941
[TBL] [Abstract][Full Text] [Related]
13. Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study.
Lin DY; Xu Y; Gu Y; Zeng D; Wheeler B; Young H; Moore Z; Sunny SK
Lancet Infect Dis; 2023 Nov; 23(11):1257-1265. PubMed ID: 37336222
[TBL] [Abstract][Full Text] [Related]
14. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting.
Rane MS; Robertson MM; Kulkarni SG; Frogel D; Gainus C; Nash D
Vaccine; 2023 Jan; 41(4):989-998. PubMed ID: 36588007
[TBL] [Abstract][Full Text] [Related]
16. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data.
Bello-Chavolla OY; Antonio-Villa NE; Valdés-Ferrer SI; Fermín-Martínez CA; Fernández-Chirino L; Vargas-Vázquez A; Ramírez-García D; Mancilla-Galindo J; Kammar-García A; Ávila-Funes JA; Zúñiga-Gil CH; García-Grimshaw M; Ceballos-Liceaga SE; Carbajal-Sandoval G; Montes-González JA; Zaragoza-Jiménez CA; García-Rodríguez G; Cortés-Alcalá R; Reyes-Terán G; López-Gatell H; Gutiérrez-Robledo LM
Int J Infect Dis; 2023 Apr; 129():188-196. PubMed ID: 36775188
[TBL] [Abstract][Full Text] [Related]
19. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022.
Hall VJ; Insalata F; Foulkes S; Kirwan P; Sparkes D; Atti A; Cole M; de Lacy E; Price L; Corrigan D; Brown CS; Islam J; Charlett A; Hopkins S;
J Infect; 2024 Jan; 88(1):30-40. PubMed ID: 37926119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
